Peters R A, Williams S G, Lombard M, Karani J, Westaby D
Dept. of Gastroenterology, Chelsea and Westminster Hospital, London, United Kingdom.
Endoscopy. 1997 Jan;29(1):10-6. doi: 10.1055/s-2007-1004054.
Treatment options for unresectable hepatic hilar strictures include percutaneous or endoscopic stent insertion, using either standard Teflon or self-expanding metal endoprostheses. The use of Teflon stents is complicated by stent migration and high occlusion rates. Published series of endoscopically placed metal stents have not concentrated on their use in the treatment of high-grade hilar strictures (Bismuth grades II and III). We therefore undertook a prospective and open pilot study to evaluate the efficacy of endoscopically placed metal endoprostheses in the palliation of jaundice due to high-grade hilar strictures.
Self-expanding metal stents were placed endoscopically in 17 patients (nine women, eight men; median age 64 years, range 33-77). Of the 17 malignancies 11 patients (65%) had a diagnosis of cholangiocarcinoma, and 12 (71%) had Bismuth grade III strictures.
The stents were inserted successfully in all 1 patients. Adequate drainage, as demonstrated by a significant reduction in bilirubin, was achieved in 1: (88%); the two patients in whom drainage failed had extensive intrahepatic disease. Early complications (cholangitis) developed in one patients (6%), and there were seven late complications (41%) in five patients (four occluded stents and three cases of duodenal compression). The stent patency appeared to be prolonged (median stent patency 12 months, range 1.5-24 months, in patients surviving five months or more). The median survival was ten months (range 1-48 months) after stent insertion. All of the patients died during follow-up.
These results suggest that endoscopically placed metal stents offer effective palliation for high grade hilar malignancies, although controlled trial comparing the use of metal and Teflon endoprostheses in this patient group are required.
不可切除的肝门部狭窄的治疗选择包括经皮或内镜下置入支架,可使用标准的聚四氟乙烯或自膨式金属内支架。聚四氟乙烯支架的使用存在支架移位和高闭塞率等问题。已发表的关于内镜下放置金属支架的系列研究尚未聚焦于其在治疗高级别肝门部狭窄(Bismuth II级和III级)中的应用。因此,我们进行了一项前瞻性开放性初步研究,以评估内镜下放置金属内支架在缓解因高级别肝门部狭窄所致黄疸方面的疗效。
对17例患者(9例女性,8例男性;中位年龄64岁,范围33 - 77岁)进行了内镜下自膨式金属支架置入。17例恶性肿瘤患者中,11例(65%)诊断为胆管癌,12例(71%)为Bismuth III级狭窄。
所有17例患者的支架均成功置入。15例(88%)患者胆红素显著降低,表明引流充分;引流失败的2例患者存在广泛的肝内病变。1例患者(6%)发生早期并发症(胆管炎),5例患者出现7例晚期并发症(41%)(4例支架闭塞和3例十二指肠受压)。支架通畅时间似乎延长(存活5个月或更长时间的患者中,中位支架通畅时间为12个月,范围1.5 - 24个月)。支架置入后的中位生存期为10个月(范围1 - 48个月)。所有患者在随访期间均死亡。
这些结果表明,内镜下放置金属支架可为高级别肝门部恶性肿瘤提供有效的姑息治疗,尽管需要进行对照试验以比较该患者群体中金属和聚四氟乙烯内支架的使用情况。